Estradiol/Norethindrone Acetate

ApprovedSmall molecule

Estradiol/Norethindrone Acetate is one of 95 small molecule programs targeting Diastolic Heart Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diastolic Heart FailureActive, not recruiting

Uterine FibroidActive, not recruiting

EndometriosisActive, not recruiting

Diastolic Heart FailureApproved

Active, not recruiting

Uterine FibroidPhase 3

Active, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Lupron

AbbVie

Phase 3

1 2

Revia

Teva

Phase 3

1 3

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

3 4

Trental

VValidus Pharmaceuticals

Phase 3

1 5

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 6

Firmagon

Ferring

Phase 3

1 7

Estradiol/Norethindrone Acetate

AbbVie

Approved

5 8

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 9

Triptorelin Embonate

Ipsen

Phase 3

1 10

Indole-3-Carbinol

UUniversity of Kansas Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uterine Fibroid8 trials

Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Completed· AbbVie logo

AbbVie·Phase 2·NCT01441635·271 enrolled

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Completed· AbbVie logo

AbbVie·Phase 3·NCT02654054·413 enrolled

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Completed· AbbVie logo

AbbVie·Phase 3·NCT02691494·378 enrolled

Show 5 more trials

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed·MMyovant Sciences GmbH·Phase 3·NCT03049735·388 enrolled

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed·MMyovant Sciences GmbH·Phase 3·NCT03103087·382 enrolled

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed· AbbVie logo

AbbVie·Phase 3·NCT02925494·433 enrolled

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed·MMyovant Sciences GmbH·Phase 3·NCT03751124·229 enrolled

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed·MMyovant Sciences GmbH·Phase 3·NCT03412890·477 enrolled

Endometriosis5 trials

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Completed·MMyovant Sciences GmbH·Phase 3·NCT03204318·638 enrolled

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03343067·11 enrolled

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Completed·MMyovant Sciences GmbH·Phase 3·NCT03654274·802 enrolled

Show 2 more trials

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Completed· AbbVie logo

AbbVie·Phase 3·NCT03213457·681 enrolled

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Completed·MMyovant Sciences GmbH·Phase 3·NCT03204331·623 enrolled

Fed1 trial

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

Completed· Teva logo

Teva·Phase 1·NCT01181726·40 enrolled

Diastolic Heart Failure1 trial

Estrogen Diastolic Heart Failure

Terminated·GGretchen Wells·Phase 4·NCT02693002·4 enrolled

Fasting Conditions1 trial

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT01157182·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Estradiol/Norethindrone Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Estradiol/Norethindrone Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Estradiol/Norethindrone Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Estradiol/Norethindrone Acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Uterine Fibroid8 trials

Endometriosis5 trials

Fed1 trial

Diastolic Heart Failure1 trial

Fasting Conditions1 trial

References

Drug Info

Quick Facts

Related News